<DOC>
	<DOCNO>NCT00891605</DOCNO>
	<brief_summary>Safety study ABT-263 Combination Paclitaxel Subjects Solid Tumors .</brief_summary>
	<brief_title>Safety Study ABT-263 Combination With Paclitaxel Subjects With Solid Tumors</brief_title>
	<detailed_description>A Phase 1 Safety Pharmacokinetic Study ABT-263 Combination Paclitaxel Treatment Subjects Solid Tumors .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria 1 . Subject must great equal 18 year age . 2 . Subject must histologically and/or cytologically documented cancer paclitaxel determine appropriate therapy , per Investigator . 3 . Subjects brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence CNS disease progression determine CT MRI within 28 day prior first dose study drug . 4 . Subject Eastern Cooperative Oncology Group ( ECOG ) score less equal 1 . 5 . Subject must adequate bone marrow , renal hepatic function per protocol define local laboratory test parameter . Exclusion Criteria 1 . The subject underlying , predispose condition bleed currently exhibit sign bleed . The subject recent history thrombocytopenia associate bleed within 1 year prior first dose study drug . 2 . Subject currently receive require anticoagulation therapy ( e.g. , warfarin dose ) drug herbal supplement affect platelet function , exception lowdose anticoagulation medication heparin use maintain patency central intravenous catheter . 3 . The subject active peptic ulcer disease potentially hemorrhagic esophagitis/gastritis . 4 . The subject active immune thrombocytopenic purpura ( ITP ) , autoimmune hemolytic anemia ( AIHA ) , history refractory platelet transfusion ( within 1 year prior first dose study drug ) . 5 . The subject significant history cardiovascular ( e.g. , MI , thrombotic thromboembolic event last 6 month ) , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease opinion investigator would adversely affect his/her participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>